Serum CXCL9 levels are much higher in patients with than without NASH, which suggests CXCL9/CXCR3 signaling as a target for the treatment of liver fibrosis [65,66]. The gene discussed is CXCL9; the disease is metabolic dysfunction-associated steatohepatitis.